Reports of viral hepatitis B and C in HIV patients participating in clinical trials of elvitegravir/cobicistat/tenofovir DF/emtricitabine and cobicistat-boosted atazanavir plus tenofovir DF/emtricitabine

被引：0
|
作者：
Quirk, E. [1 ]
Graham, H. [1 ]
Liu, C. [1 ]
Rhee, M. [1 ]
Piontkowsky, D. [1 ]
Szwarcberg, J. [1 ]
机构：
[1] Gilead Sci, Foster City, CA USA
来源：
ANTIVIRAL THERAPY | 2013年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：A63 / A63
页数：1
相关论文
共 50 条
  • [1] Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV patients with renal impairment
    Post, F.
    Andrade-Villanueva, J.
    Fisher, M.
    Winston, J.
    Liu, Y.
    Zhong, L.
    Cheng, A.
    Rhee, M.
    Szwarcberg, J.
    [J]. HIV MEDICINE, 2014, 15 : 115 - 115
  • [2] Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Atazanavir plus Ritonavir plus Emtricitabine/Tenofovir DF in Antiretroviral-Naive Patients
    Kulkarni, Rima
    Abram, Michael E.
    McColl, Damian J.
    Barnes, Tiffany
    Fordyce, Marshall W.
    Szwarcberg, Javier
    Cheng, Andrew K.
    Miller, Michael D.
    White, Kirsten L.
    [J]. HIV CLINICAL TRIALS, 2014, 15 (05): : 218 - 229
  • [3] Week 96 efficacy and safety data: Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF in treatment-naive HIV-1-infected patients
    Orkin, C.
    Rockstroh, J.
    DeJesus, E.
    Henry, K.
    Molina, J.
    Gathe, J.
    Wei, X.
    Fordyce, M.
    Rhee, M.
    Smith, A.
    Szwarcberg, J.
    [J]. HIV MEDICINE, 2013, 14 : 56 - 56
  • [4] Resistance analyses of the elvitegravir/cobicistat/emtricitabine/tenofovir DF switch studies
    Andreatta, K.
    Kulkarni, R.
    Abram, M. E.
    Nguyen, T.
    Cao, H.
    Miller, M. D.
    White, K. L.
    [J]. ANTIVIRAL THERAPY, 2014, 19 : A144 - A144
  • [5] Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients
    White, Kirsten L.
    Kulkarni, Rima
    McColl, Damian J.
    Rhee, Martin S.
    Szwarcberg, Javier
    Cheng, Andrew K.
    Miller, Michael D.
    [J]. ANTIVIRAL THERAPY, 2015, 20 (03) : 317 - 327
  • [6] Simplification to elvitegravir/cobicistat/emtricitabine/tenofovir DF from ritonavir-boosted protease inhibitor plus emtricitabine/tenofovir DF maintains HIV suppression and improves fasting triglycerides at week 48
    Mounzer, K.
    Rashbaum, B.
    Lucasti, C.
    Melbourne, K.
    Kwon, P.
    Nguyen, T.
    [J]. ANTIVIRAL THERAPY, 2014, 19 : A26 - A27
  • [7] Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF at week 96 in treatment-na ve HIV-1-infected patients
    Rockstroh, J.
    DeJesus, E.
    Henry, K.
    Molina, J.
    Gathe, J.
    Wei, X.
    Fordyce, X.
    Rhee, M.
    Szwarcberg, J.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 23 - 23
  • [8] Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF in HIV-Infected Patients With Mild-to-Moderate Renal Impairment
    Post, Frank A.
    Winston, Jonathan
    Andrade-Villanueva, Jaime F.
    Fisher, Martin
    Liu, YaPei
    Beraud, Christophe
    Abram, Michael E.
    Graham, Hiba
    Rhee, Martin S.
    Cheng, Andrew K.
    Szwarcberg, Javier
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2015, 68 (03) : 310 - 313
  • [9] Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir plus Ritonavir plus Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128)
    Kulkarni, Rima
    Hodder, Sally L.
    Cao, Huyen
    Chang, Silvia
    Miller, Michael D.
    White, Kirsten L.
    [J]. HIV CLINICAL TRIALS, 2017, 18 (04): : 164 - 173
  • [10] A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results
    Rockstroh, Juergen K.
    DeJesus, Edwin
    Henry, Keith
    Molina, Jean-Michel
    Gathe, Joseph
    Ramanathan, Srinivasan
    Wei, Xuelian
    Plummer, Andrew
    Abram, Michael
    Cheng, Andrew K.
    Fordyce, Marshall W.
    Szwarcberg, Javier
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 62 (05) : 483 - 486
12345